Literature DB >> 29055040

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors.

Stephen Ph Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6, Adam J Pawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6.   

Abstract

The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
© 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29055040      PMCID: PMC5650667          DOI: 10.1111/bph.13878

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  3 in total

1.  Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.

Authors:  C Serradeil-Le Gal; D Raufaste; E Double-Cazanave; G Guillon; C Garcia; M Pascal; J P Maffrand
Journal:  Kidney Int       Date:  2000-10       Impact factor: 10.612

2.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors.

Authors:  Stephen Ph Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

3.  The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency.

Authors:  R A Galemmo; W H Johnson; K S Learn; T D Lee; F C Huang; H F Campbell; R Youssefyeh; S V O'Rourke; G Schuessler; D M Sweeney
Journal:  J Med Chem       Date:  1990-10       Impact factor: 7.446

  3 in total
  422 in total

1.  Knockdown of the transcript of ERK in the brain modulates hypothalamic neuropeptide-mediated appetite control in amphetamine-treated rats.

Authors:  Ching-Han Yu; Yih-Shou Hsieh; Pei-Ni Chen; Jeng-Rung Chen; Dong-Yih Kuo
Journal:  Br J Pharmacol       Date:  2018-01-11       Impact factor: 8.739

2.  N-Ethylmaleimide differentiates between the M2- and M4-autoreceptor-mediated inhibition of acetylcholine release in the mouse brain.

Authors:  Justine Etscheid; Klaus Mohr; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-21       Impact factor: 3.000

3.  VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Authors:  Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

4.  Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins.

Authors:  Yi-Lynn Liang; Matthew J Belousoff; Madeleine M Fletcher; Xin Zhang; Maryam Khoshouei; Giuseppe Deganutti; Cassandra Koole; Sebastian G B Furness; Laurence J Miller; Debbie L Hay; Arthur Christopoulos; Christopher A Reynolds; Radostin Danev; Denise Wootten; Patrick M Sexton
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-20

Review 5.  Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12.

Authors:  Paula Morales; Israa Isawi; Patricia H Reggio
Journal:  Drug Metab Rev       Date:  2018-02-01       Impact factor: 4.518

Review 6.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

7.  The opioid oxycodone use-dependently inhibits the cardiac sodium channel NaV 1.5.

Authors:  Jannis E Meents; Krisztina Juhasz; Sonja Stölzle-Feix; Vera Peuckmann-Post; Roman Rolke; Angelika Lampert
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 8.  Hydrogen sulfide and dermatological diseases.

Authors:  Silvia A Coavoy-Sánchez; Soraia K P Costa; Marcelo N Muscará
Journal:  Br J Pharmacol       Date:  2019-06-18       Impact factor: 8.739

9.  First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

Authors:  Priska Kaufmann; Marion Ort; Georg Golor; Rüdiger Kornberger; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

10.  Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M1 receptors.

Authors:  Lisa M Broad; Helen E Sanger; Adrian J Mogg; Ellen M Colvin; Ruud Zwart; David A Evans; Francesca Pasqui; Emanuele Sher; Graham N Wishart; Vanessa N Barth; Christian C Felder; Paul J Goldsmith
Journal:  Br J Pharmacol       Date:  2018-11-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.